secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0001193125-22-087458
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dr. Kauffman and Dr. Shacham to depart Karyopharm on May 31, 2022
-----------------------------------------------------------------

- Dr. Michael Kauffman to depart as Senior Clinical Advisor; receives 18 months salary at $646,875/yr.
- Dr. Sharon Shacham to depart as CSO; receives 18 months salary at $519,901/yr and consulting role.
- Both executives get accelerated vesting of equity awards; options exercisable until March 1, 2025.
- Dr. Shacham receives new grants: 90,000 stock options and 60,000 RSUs under consulting agreement.
- Dr. Kauffman resigned from Board on March 22, 2022; waived nomination rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/d344096d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-087458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer